Novel GM1 Delivery Method Shows Promise in ALS Treatment
A new approach to delivering a natural molecule called GM1 to the brain is showing promising results in laboratory testing for the treatment of amyotrophic lateral sclerosis (ALS), as well known as Lou Gehrig’s disease. Researchers at the University of Missouri (Mizzou) have successfully encapsulated GM1 within tiny, fat-based bubbles to overcome the challenges of the blood-brain barrier.
Understanding ALS and the Challenges of Treatment
ALS is a neurodegenerative disease that progressively weakens muscles, impacting speech, movement, and breathing. The disease is notoriously difficult to treat due to the complex breakdown of neural pathways and the protective blood-brain barrier, which prevents many potential therapeutics from reaching the brain. Previous attempts to deliver GM1 directly to the brain have been unsuccessful due to this barrier. University of Missouri
The Breakthrough: GM1 in a Fat-Based Bubble
Smita Saxena, a professor in the School of Medicine at Mizzou, led the study demonstrating that GM1 can effectively reach the brain when packaged inside a microscopic lipid bubble. This delivery system, known as Talineuren, has previously been used in human clinical trials for Parkinson’s disease, making it a potentially safe and effective method for delivering GM1 to treat ALS symptoms. University of Missouri
How the Therapy Works
Research indicates that neurons in individuals with ALS are particularly sensitive to endoplasmic reticulum stress, which impairs the mitochondria’s ability to produce energy. This energy deficit hinders the neurons’ ability to transmit signals to muscles. The therapy aims to address this by improving the health of motor neurons and enhancing their function. In laboratory tests with mice exhibiting an ALS-causing mutation, the therapy successfully crossed the blood-brain barrier and improved motor function. University of Missouri
Future Directions: Clinical Trials and Proactive Treatment
The research team hopes to initiate human clinical trials at the Roy Blunt NextGen Precision Health building to assess the therapy’s effectiveness in improving motor function in ALS patients. Researchers also envision a potential proactive approach, administering the therapy to younger individuals who have inherited the disease-causing mutation, potentially halting the progression of ALS before symptoms even appear. University of Missouri
About Smita Saxena
Smita Saxena, PhD, is a professor in the Department of Physical Medicine and Rehabilitation at the University of Missouri and a NextGen Precision Health Investigator. Her research focuses on understanding the mechanisms of neuronal vulnerability in neurodegenerative diseases, with a specific emphasis on ALS. National Center for Biotechnology Information
“Engineered GM1 intersects between mitochondrial and synaptic pathways to ameliorate ALS pathology” was published in Advanced Science. University of Missouri